Company intelligence / Profile preview

SMSbiotech

San Diego, California, USAsmsbiotech.com ↗

Ownership: Private
Employees: ~13
Development stage: Phase 1

Overview

SMSbiotech has developed a patented platform based on novel human allogeneic adult Small Mobile Stem Cells. The company’s technology aims to address tissue degeneration underlying chronic and age-related diseases such as COPD, ARDS, and chronic wounds. As of now, the company remains in the pre-clinical stage with no reported clinical trial results.

Therapeutic areas: PulmonologyDermatology
Modalities: Cell therapy (allogeneic adult stem cells)
Industry: Biotech

Drug pipeline

2 assets

small mobile stem cells

1 more asset in the full pipeline.

Request access →

Partnerships

Collaborations with scientific institutions and leading research organizations are mentioned but not named specifically.

Beyond the preview

Go deeper on SMSbiotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SMSbiotech.

Explore the full profile